Medical Director, Center for Sweat Disorders

Professor of Surgery

Research Interests: Translating Basic Research into the Clinic; Tumor Biology of Lung and Esophageal Cancer; Biomarkers as predictors of cancer detection; Prognosis and Chemotherapy Sensitivity; Hyperhidrosis; Epigenetics research for cancer treatment ...read more

Locations

Background

Malcolm V. Brock, M.D., a graduate of the Johns Hopkins University School of Medicine, the Johns Hopkins general surgical residency program and the Johns Hopkins fellowship in cardiothoracic surgery, is a specialist in thoracic oncology, and is an Associate Professor of Surgery and Oncology at the Johns Hopkins University School of Medicine. In additional to clinical thoracic oncology, his clinical interests include surgery for palmar, axillary and pedal hyperhydrosis.

Board-certified in general and thoracic surgery, Dr. Brock is a surgeon who conducts cancer research at the Johns Hopkins Kimmel Cancer Center, specializing in applying innovative basic science research to patient care. His main research interests are in developing novel molecular biomarkers for solid tumors that can help clinicians diagnose cancer earlier and treat it more effectively. He has studied using DNA-based methods to predict which patients will develop recurrent lung cancer, even after successful surgery, and to predict patients with esophageal cancer who will be sensitive to certain chemotherapy. Dr. Brock has published over 70 original research papers, book chapters and review articles, and has presented often at national and international conferences. He has been the recipient of research funding from the National Institutes of Health (NIH), the Thoracic Surgery Foundation for Research Excellence, the American College of Surgery Oncology Group and the Society of Surgical Oncology.

Board Certifications

Research & Publications

Selected Publications

Dr. Brock's research has focused primarily on developing and clinically applying molecular biomarkers, namely DNA methylation, to facilitate the early detection, accurate prognosis and specific chemosensitivity of lung and esophageal cancers. Current projects include using DNA methylation as a more accurate molecular indicator of lymph micrometases in a large cohort of lung cancer patients and as a means of predicting sensitivity of esophageal cancer to neoadjuvant chemotherapy based on endoscopic biopsy samples. Dr. Brock actively collaborates with Drs. Stephen Baylin and James Herman in the Division of Tumor Biology in the Cancer Center. Recently, Dr. Brock has received NIH funding to investigate the rising incidence of lung cancer in HIV patients and has begun both a clinical study and a tumor-profiling project in this regard. Finally, the Brock laboratory has developed large relational databases of lung and esophageal patients with matching biological samples to validate biomarker discovery.